BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hospira, Inc. (HSP) CEO Takes 29 Pct Pay Cut


4/1/2013 11:44:42 AM

Struggling with production problems and federal drug regulators, Hospira Inc. hacked CEO F. Michael Ball's compensation by almost 29 percent, to $8.8 million last year, compared with 2011. Mr. Ball's compensation plunged from $12.4 million in 2011, when the Lake Forest-based medical products company gave him a lucrative package to entice him to leave Irvine, Calif.-based Allergan Inc., where he was president. Hospira's “financial results and operational performance were impacted by the supply challenges and increased costs resulting from the company's quality improvement efforts,” the company said in a proxy statement filed today with the Securities and Exchange Commission. As a result, no senior executive's cash bonus was more than 43.5 percent of the target. Mr. Ball's 2012 cash bonus was just $518,000, or 43.5 percent of the targeted $1.2 million. On March 5, the Lake Forest injectable drug manufacturer revealed that the Food and Drug Administration had again inspected its plant in Rocky Mount, N.C. and reported 20 negative findings, three of which had surfaced earlier. The company has “systemic” quality problems, according to a reportreleased two weeks ago by an analyst at New York-based RBC Capital Markets.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES